Importantly, hepatic NIK is aberrantly activated in both mice and humans with NAFLD or alcoholic liver disease (Sheng et al., 2012; Shen et al., 2014). Here, MAP3K14 is linked to metabolic dysfunction-associated steatotic liver disease.